Drug Profile
Research programme: hepatitis B ribozyme therapy - Viratis
Latest Information Update: 11 May 2010
Price :
$50
*
At a glance
- Originator Viratis
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 13 Aug 2007 Preclinical trials in Hepatitis B in United Kingdom (unspecified route)